Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in multiple myeloma patients
IRCT20210415050976N16Phase 2Completed
- Sponsor
- Jahrom University of Medical Sciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Jahrom University of Medical Sciences. Primary endpoints: nausea and vomiting. Started Apr 2026; status: completed.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on IRCT20210415050976N16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210415050976N16.